ePrints

Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study

Lookup NU author(s): Professor Graham Jackson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Thalidomide maintenance has unresolved issues regarding dosage and toxicity. We evaluated this in five dose cohorts in 100 patients. At a median follow-up of 32.3 months, 23 patients had stopped thalidomide for disease progression, 54 for side effects. 3-year overall and progression-free survival was 76% and 41% respectively. Dosage did not influence disease outcome but greatly affected toxicity. Fifteen patients converted from partial remission to complete remission on thalidomide at a median of 13.5 months. Maintenance doses > 200 mg were largely unachievable and peripheral neuropathy was the main toxicity. Lower doses enabled more patients to stay on the drug for a useful period of time.

Publication metadata

Author(s): Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ

Publication type: Article

Publication status: Published

Journal: British Journal of Haematology

Year: 2007

Volume: 139

Issue: 3

Pages: 429-433

ISSN (print): 0007-1048

ISSN (electronic): 1365-2141

Publisher: Wiley-Blackwell Publishing Ltd.

URL: http://dx.doi.org/10.1111/j.1365-2141.2007.06817.x

DOI: 10.1111/j.1365-2141.2007.06817.x

Altmetrics

Share